Attached files
| file | filename |
|---|---|
| EX-99 - EXHIBIT 99 - PFIZER INC | a50679919ex99.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 30, 2013
PFIZER INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
1-3619
|
13-5315170
|
|
(State or other
|
(Commission File
|
(I.R.S. Employer
|
|
jurisdiction of
|
(Number)
|
Identification No.)
|
|
235 East 42nd Street
|
10017
|
|
New York, New York
|
(Zip Code)
|
|
(Address of principal executive offices)
|
|
Registrant's telephone number, including area code:
(212) 733-2323
Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition
On July 30, 2013, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the second quarter of 2013. The information contained in the press release is deemed to be “filed” under the Securities Exchange Act of 1934 as Exhibit 99 to this report, and such press release is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit 99 - | Press Release of Pfizer Inc. dated July 30, 2013, reporting Pfizer's financial results for the second quarter of 2013. Exhibit 99 is deemed to be “filed” under the Securities Exchange Act of 1934 in this Current Report on Form 8-K. |
SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.
|
PFIZER INC.
|
||
|
By:
|
/s/ Matthew Lepore
|
|
|
Matthew Lepore
|
||
|
Vice President and Corporate Secretary
|
||
Dated: July 30, 2013
EXHIBIT INDEX
| Exhibit No. | Description |
| 99 | Press Release of Pfizer Inc. dated July 30, 2013, reporting Pfizer's financial results for the second quarter of 2013. |